Key result
Pulmonary endarterectomy remains the treatment of choice for operable chronic thromboembolic pulmonary hypertension, while targeted medical therapies offer options for inoperable or persistent cases.
Pulmonary endarterectomy remains the definitive treatment for operable CTEPH, while emerging medical therapies offer options for inoperable patients or those with residual pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Supports pulmonary endarterectomy as first-line for operable CTEPH; extends evidence for targeted therapies in inoperable cases but leaves sequencing questions open.
Chronic pulmonary thromboembolic disease is an important cause of severe pulmonary hypertension, and as such is associated with significant morbidity and mortality. The prognosis of this condition reflects the degree of associated right ventricular dysfunction, with predictable mortality related to the severity of the underlying pulmonary hypertension. Left untreated, the prognosis is poor. Pulmonary endarterectomy is the treatment of choice to relieve pulmonary artery obstruction in patients with chronic thromboembolic pulmonary hypertension and has been remarkably successful. Advances in surgical techniques along with the introduction of pulmonary hypertension-specific medication provide therapeutic options for the majority of patients afflicted with the disease. However, a substantial number of patients are not candidates for pulmonary endarterectomy due to either distal pulmonary vascular obstruction or significant comorbidities. Therefore, careful selection of surgical candidates in expert centres is paramount. The current review focuses on the diagnostic approach to chronic thromboembolic pulmonary hypertension and the available surgical and medical therapeutic options.
No takes yet. Share an insight, caveat, or question.
Schölzel et al. (2014) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary endarterectomy and pulmonary vasodilator therapy was evaluated. Pulmonary endarterectomy remains the treatment of choice for operable chronic thromboembolic pulmonary hypertension, while targeted medical therapies offer options for inoperable or persistent cases.
Synapse has enriched 10 related papers. Consider them for comparative context: